G13.0
Paraneoplastic neuromyopathy and neuropathy
Clinical Classification Guidelines
Inclusion Terms
- Carcinomatous neuromyopathy
- Sensorial paraneoplastic neuropathy [Denny Brown]
Code First
- underlying neoplasm (C00-D49)
Medical Intelligence & Overview
Paraneoplastic neuromyopathy and neuropathy are rare neurological conditions associated with cancer. They result from an abnormal immune response triggered by a tumor, which mistakenly attacks the nervous system. These conditions encompass a range of nerve and muscle disorders that can develop before or after a cancer diagnosis, often serving as a harbinger of an underlying malignancy. Recognized under ICD-10 code G13.0, they can significantly impact a person's quality of life and require careful evaluation for early diagnosis and management.
Causes & Symptoms
Clinical Causes: Lung cancers, particularly small cell lung carcinoma Gastrointestinal cancers, such as gastric or pancreatic carcinoma Testicular tumors Breast cancer Lymphomas and other hematologic malignancies Other solid tumors producing paraneoplastic syndromes
Key Symptoms: Sensory disturbances like numbness, tingling, or burning sensations, often in the hands and feet Muscle weakness, especially in distal limbs Difficulty coordinating movements or maintaining balance Autonomic dysfunction such as irregular blood pressure, abnormal sweating, or digestive issues Muscle pain or cramping Reflex changes, including decreased or absent reflexes Potential involvement of cranial nerves, leading to facial weakness or difficulty swallowing
Diagnostic & Treatment
Diagnosis Path: Detailed medical history focusing on neurological symptoms and cancer risk factors Physical and neurological examinations to assess sensory and motor function Electrophysiological tests like nerve conduction studies and electromyography (EMG) to evaluate nerve and muscle activity Blood tests to identify specific autoantibodies commonly associated with paraneoplastic syndromes Imaging studies, including CT scans or MRIs, to locate the primary tumor Biopsy procedures if necessary, to confirm cancer type and rule out other causes
Treatment Protocols: Oncologic therapies such as surgery, chemotherapy, radiotherapy, or targeted treatments to eliminate or control the primary tumor Immunotherapy options like corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis to modulate immune activity Supportive therapies including physical therapy, occupational therapy, and pain management to improve function and quality of life Regular monitoring and supportive care tailored to individual needs
Clinical Advice & FAQs
Billing Guidance
Is G13.0 a billable ICD-10 code?
Yes, G13.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G13.0?
Clinical documentation must specify the nature of Paraneoplastic neuromyopathy and neuropathy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference